Cronos Group (CRON) Stock Price, News & Analysis

Company Overview

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Key Stats

• Today's Range: C$3.85 to C$4.00
• 50-Day Range: C$3.47 to C$3.98
• 52-Week Range: C$2.58 to C$4.66
• Volume: 107,147 shs
• Average Volume: 175,457 shs
• Market Capitalization: C$1.49 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$4.75
• Consensus Rating: Buy

Cronos Group Stock Analysis - MarketRank™

Cronos Group scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Buy

Consensus Rating

Cronos Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Cronos Group has a consensus price target of C$4.75, representing about 19.3% upside from its current price of C$3.98.

Amount of Analyst Coverage

Cronos Group has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cronos Group is -188.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cronos Group is -188.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Cronos Group has a PEG Ratio of 0.12. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Cronos Group has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CRON.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cronos Group does not currently pay a dividend.

Dividend Growth

Cronos Group does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 5 people have searched for CRON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cronos Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

46.40% of the stock of Cronos Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

4.57% of the stock of Cronos Group is held by institutions.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 6/26/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:CRON
• CIK: N/A
• Web: www.thecronosgroup.com
• Phone: 416-504-0004
• Fax: N/A
• Employees: 450
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cronos Group: C$4.75
• High Price Target: C$5.50
• Low Price Target: C$4.25
• Potential Upside/Downside: +19.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 0.12
• Net Income: -C$32.78 million
• Net Margins: -1.29%
• Pretax Margin: N/A
• Return on Equity: -0.19%
• Return on Assets: -3.73%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 21.87
• Quick Ratio: 24.01

Sales & Book Value

• Annual Sales: C$159.54 million
• Price / Sales: 9.32
• Cash Flow: C$2.38 per share
• Price / Cash Flow: 1.67
• Book Value: C$2.96 per share
• Price / Book: 1.34

Miscellaneous

• Outstanding Shares: 373,662,000
• Free Float: N/A
• Market Cap: C$1.49 billion
• Optionable: Not Optionable
• Beta: 1.13